3 Stocks to Buy Under $10 That Could Triple From Here

Sana has also significantly expanded its financial runway by raising funds through an at-the-market sale and a public equity offering. It ended the second quarter with $72.7 million in cash, which increased to a pro forma $177.2 million after the capital raises. The company expects this to fund operations until the second half of 2026. Sana's breakthrough for diabetes is one of the most promising initiatives to date in developing a functional treatment that does not require lifelong immunosuppression. This ...